Takeda Pharmaceutical (NYSE:TAK) Issues FY 2025 Earnings Guidance

Key Points

• Takeda Pharmaceutical updated its FY 2025 earnings guidance, projecting earnings per share of $3.36 and revenue of $31.3 billion.
• Morgan Stanley upgraded Takeda's rating from "equal weight" to "overweight", indicating increased confidence in the company's performance.
• The stock is currently trading around $14.32, with a market capitalization of $45.55 billion and a price-to-earnings ratio of 65.07.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 3.360-3.360 for the period. The company issued revenue guidance of $31.3 billion-$31.3 billion.

Takeda Pharmaceutical Trading Up 3.3%

TAK traded up $0.45 on Friday, hitting $14.17. 6,215,654 shares of the company were exchanged, compared to its average volume of 4,714,807. The firm has a fifty day simple moving average of $14.86 and a two-hundred day simple moving average of $14.52. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.52 and a current ratio of 1.16. Takeda Pharmaceutical has a 12 month low of $12.80 and a 12 month high of $15.53. The stock has a market capitalization of $45.09 billion, a PE ratio of 47.23 and a beta of 0.22.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. The company had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. Sell-side analysts expect that Takeda Pharmaceutical will post 1.64 earnings per share for the current year.

Institutional Investors Weigh In On Takeda Pharmaceutical

A number of large investors have recently made changes to their positions in the business. Focus Partners Wealth boosted its position in shares of Takeda Pharmaceutical by 4.1% during the first quarter. Focus Partners Wealth now owns 82,738 shares of the company's stock valued at $1,230,000 after purchasing an additional 3,239 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Takeda Pharmaceutical by 11.0% during the first quarter. Royal Bank of Canada now owns 441,054 shares of the company's stock valued at $6,558,000 after purchasing an additional 43,706 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Takeda Pharmaceutical by 43.6% during the first quarter. AQR Capital Management LLC now owns 195,740 shares of the company's stock valued at $2,911,000 after purchasing an additional 59,442 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in shares of Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company's stock valued at $79,120,000 after purchasing an additional 692,404 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.